menu
    • menu

    Company profile for Tempero Bio

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. At Tempero Bio, we’re focused on advancing transformative therapies...
    Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for Substance Use Disorders and related disorders. Tempero Bio is a portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. At Tempero Bio, we’re focused on advancing transformative therapies that treat and prevent substance use disorders and recover lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tempero BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1111 Broadway #1300 Oakland, CA 94607
    Telephone
    Telephone
    +1 (510) 227-2102
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.temperobio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tempero-bio-inc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/temperobio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tempero Winding Down Following Serious Adverse Event
    Tempero Winding Down Following Serious Adverse Event

    24 Apr 2026

    // BIOSPACE

    https://www.biospace.com/biospace-layoff-tracker

    BIOSPACE
    24 Apr 2026
    Share Share
    Tempero Biotech To Shut Down Following Prior Safety Concerns
    Tempero Biotech To Shut Down Following Prior Safety Concerns

    23 Apr 2026

    // ENDPOINTS

    https://endpoints.news/substance-use-disorder-biotech-tempero-to-close-after-earlier-serious-safety-event/

    ENDPOINTS
    23 Apr 2026
    Share Share
    Tempero Pauses Alcohol Disorder Work, Mulls Options: Nxera
    Tempero Pauses Alcohol Disorder Work, Mulls Options: Nxera

    03 Nov 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/tempero-calls-time-alcohol-use-disorder-while-mulling-options-according-partner

    FIERCE BIOTECH
    03 Nov 2025
    Share Share
    Tempero Bio Secures $70 Million Series B Financing
    Tempero Bio Secures $70 Million Series B Financing

    24 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tempero-bio-secures-70-million-series-b-financing-to-advance-tmp-301-into-phase-2-trials-for-substance-use-disorders-302408403.html

    PR NEWSWIRE
    24 Mar 2025
    Share Share
    Tempero Bio Announces FDA Clearance of IND Application for TMP-301
    Tempero Bio Announces FDA Clearance of IND Application for TMP-301

    04 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tempero-bio-announces-fda-clearance-of-investigational-new-drug-ind-application-for-tmp-301-for-the-treatment-of-alcohol-and-other-substance-use-disorders-301712859.html

    PR NEWSWIRE
    04 Jan 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search